Objective. Human umbilical cord Wharton jelly-derived mesenchymal stem cells (hUCMS) are easy to retrieve in bulk. They may interact with immune cells by either cell contact or soluble factors. Little evidence is currently available on potential therapeutic application of hUCMS to systemic autoimmune disorders such as primary SS (pSS). We have recently developed an endotoxin-free alginate gel that can be used to microencapsulate different cell types for graft into non-immunosuppressed hosts. We aimed to assess the in vitro effects of IFN-g-pretreated microencapsulated (CpS)-hUCMS on T cells of pSS.
Introduction
Primary SS (pSS) is a systemic autoimmune disorder characterized by chronic inflammation of exocrine glands leading to secretory function impairment and tissue damage [1] in which Th17 cells represent a main pathogenic effector subset involved in autoimmunity and glandular tissue injury [2] . An intriguing aspect of Th17 cell homeostasis is the relationship with Tregs, whose imbalance may lead to the development of autoimmune diseases [3, 4] .
The course of the disease is rather mild in many patients, but a subgroup of subjects can experience severe extraglandular involvement and often currently available treatments in these cases are not efficacious [5] . Therefore the identification of therapeutic alternatives is desirable.
Human umbilical cord mesenchymal stem cells (hUCMS) are adult stem cells able to differentiate into several cell phenotypes [6] . They display homing properties, are immunoprivileged, owing to the lack of HLA-DR, and exhibit immunomodulatory properties. Their properties seem to depend on both humoral factors, including TGF-b1, indoleamine 2,3-dioxygenase (IDO), nitric oxide (NO), IL-6, prostaglandin E2, hepatocyte growth factor and VEGF, and their interaction with target cells.
Despite the therapeutic potential of hUCMS, limitations associated with direct grafting procedures prevent effective hUCMS transplantation within the framework of safe and controlled therapeutic protocols [7] . We recently completed clinical application of human islets of Langerhans, microencapsulated in immunoprotective alginate-based microcapsules in patients with type 1 diabetes mellitus (T1D). This procedure allowed avoidance of the recipient's general immune suppression (Italian Ministry of Health no. 19382, PRE805; Clinical Trial Registration ISRCTN43557935) [8] . We employed the microencapsulation technique to arrange a co-culture system ensuring a separation between hUCMS and peripheral blood mononuclear cells (PBMCs) for further analysis upon IFN-g incubation [9] . The aim of this study was to demonstrate whether microencapsulated (CpS)-hUCMS represent a possible and viable therapeutic alternative to conventional immunosuppressive agents in pSS.
Material and methods

Study population
Ten female patients with pSS classified according to the Euro-American criteria [10] and 10 sex-and age-matched healthy subjects [healthy donors (HDs)] were enrolled. None of the patients was receiving corticosteroids or immunosuppressants. Disease activity was assessed using the European League Against Rheumatism (EULAR) SS disease activity index [11] . The study was approved by the local ethics committee (CEAS Umbria) and written informed consent was obtained from participants in accordance with the Declaration of Helsinki.
hUCMS procurement, isolation and culture Isolation of hUCMS was performed from post-partum human umbilical cords as described by Montanucci et al. [6] .
hUCMS microencapsulation and stimulation with IFN A 1.8% endotoxin-free sodium alginate solution, employed for cell encapsulation, was prepared according to our protocol (patent WO2009093184A1) [12] . Briefly, cell pellets were mixed in 1.8% alginate solution so as to make a final homogeneous suspension. The alginate:hUCMS ratio was adjusted so as to match 1 ml of alginate to 3 Â 10 6 cells in order to avoid formation of empty capsules. CpS-hUCMS were triggered overnight with 300 U/ml IFN-g (Sigma-Aldrich, St Louis, MO, USA) that was removed before setting up the co-culture with PBMCs.
Cell cultures
PBMCs were isolated by gradient separation, stained with carboxyfluorescein succinimidyl ester (CFSE), activated with anti-CD3/CD28-coated beads (Dynabeads, Invitrogen, Carlsbad, CA, USA) and plated with hUCMS at different ratios. Unstimulated and CD3-CD28-triggered PBMCs acted as negative and positive controls, respectively. CFSE dilution was analysed on day 5 using a FACSCalibur flow cytometer and CellQuestPro software (BD Biosciences, San Jose, CA, USA).
Phenotypic analysis
Th1, Th17 and Treg cells were identified by flow cytometry as described by Alunno et al. [4, 13] .
Cytokine assessment
In the culture supernatant, concentrations of IL-17, IL-2, IL-10, TNF-a, IL-6 and TGF-b were assessed by the cytometric bead array technique (BD Bioscience) and analysed by flow cytometry.
Transcriptional expression analysis by RT-PCR and quantitative PCR Total cellular RNA was extracted from the cultured cells using the TRI-reagent method (Bio-Rad Laboratories, Segrate, Italy). cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories) and was used as a template in quantitative PCR (qPCR) (see supplementary Table S1 , available at Rheumatology Online). qPCR amplifications were performed using the SsoFast EvaGreen Supermix (Bio-Rad Laboratories) and MxPro 3000 system (Stratagene, La Jolla, CA, USA).
Western blotting
Total protein was extracted and assayed as described [6] . Protein samples (40 mg) were analysed on 10% or 12% SDS-PAGE and transferred onto nitrocellulose membrane (Bio-Rad Laboratories). Immunodetection was performed with the Immun-Star HRP Chemiluminescent kit (Bio-Rad Laboratories) (see supplementary Table S2 , available at Rheumatology Online).
Statistical analysis
Cuzick's trend test, KruskallWallis test with Dunn's test for multiple comparisons post hoc and MannWhitney U test were employed. The significance level was two-sided and set at P < 0.05. All data analysis was performed using SPSS version 20.0 (IBM, Armonk, NY, USA).
Results
In previously published studies, free hUCMS were employed at a 1:1 ratio or in excess with respect to PBMCs, revealing good suppressive activity. We confirmed that free hUCMS inhibit HD T cell proliferation at a 1:1 ratio, but most interestingly we demonstrated that such inhibition was even more evident by progressively reducing hUCMS in culture (Fig. 1A) . Similarly, CpShUCMS to reduced HD T cell proliferation at a 1:1 ratio and such inhibition was progressively more pronounced by decreasing hUCMS number (Fig. 1C) . In pSS, free hUCMS did not display inhibitory effects (Fig. 1B) , while CpS-hUCMS were able to reduce T cell proliferation (Fig. 1D) . In particular, the inhibitory effect of CpS-hUCMS was more pronounced in pSS than in HD T cells. Supplementary Fig. S1 (available at Rheumatology Online) displays an evaluation of the morphology and viability of hUCMS co-cultured with PBMCs. In agreement with functional assays, a reduction in both Th1 and Th17 cell subsets was observed in the presence of CpShUCMS in HDs. Conversely, free hUCMS, which failed to inhibit pSS T cell proliferation, were able to reduce Th1 but not Th17 cells (Fig. 1E and G) . Finally, CpShUCMS were able to decrease both Th1 and Th17 cells in pSS ( Fig. 1F and H) . As free hUCMS did not show suppressive activity on pSS Th17 cells, in subsequent experiments we only used CpS-hUCMS.
Since mesenchymal stem cells can up-regulate Treg transcription factor FoxP3 and Th17/Treg plasticity is well established [14] , we speculated that Th17 cell (Fig. 1J) . The evidence that several IFN-g-inducible factors were unchanged in culture supernatants of pSS co-cultures (see supplementary Fig. S2 and supplementary material section S1, available at Rheumatology Online; evaluation of cytokines in culture supernatants) prompted us to investigate other IFN-g-inducible mediators in CpS-hUCMS. TGF-b, IL-10 and cyclooxygenase 2 (COX-2) expression was not increased by IFN-g, while prostaglandin E synthase 2 (PTGES2) expression was up-regulated ( Fig. 2A) . We also observed a significant IL-6 up-regulation in IFNg-stimulated hUCMS, which may explain the massive presence of this cytokine in the cell culture supernatants. HLA-G5 mRNA was undetectable in resting and IFNg-stimulated CpS-hUCMS. Intriguingly, IDO1 mRNA was massively up-regulated following IFN-g stimulation ( Fig. 2B and D) . Finally, IFN-g stimulation also induced an increase in inducible nitric oxide synthase (iNOS) mRNA, but not protein ( Fig. 2C and E) , as previously demonstrated [15] .
Discussion
We demonstrated that IFN-g-stimulated CpS-hUCMS exert positive immunological effects in pSS by reducing pathogenic T cell subsets and potentiating regulatory counterparts. Although the immunomodulatory effects of free hUCMS are well known [16] , their administration for therapeutic purposes has shown several limits, mainly related to safety issues. In this study we used microbioreactors as a drug delivery system, which is already employed in patients with T1D [8] . Our technology provides a means for hUCMS transplantation without host immunosuppression, which would otherwise be necessary for free hUCMS grafting procedures. Additionally, the present data support the operative use of a very low CpShUCMS therapeutic mass. Finally, CpS-hUCMS represent a dynamic and immune-isolatory system that does not impair crosstalk with the surrounding environment. Unlike RA, free cell contact with pSS lymphocytes may weaken the suppressive activity of hUCMS, and this provides a rationale for microencapsulating hUCMS when faced with pSS-derived lymphocytes. Even though ligandreceptor interactions occurring between T cells and hUCMS may be the same in HDs and RA and pSS patients, differences may reside in the intracellular signalling apparatus, with negative feedback following hUCMS contact with pSS T cells. Alternatively, activated lymphocytes from patients express a set of peculiar surface molecules that may account for the different ligandreceptor interactions. Further experiments aimed at identifying mechanisms involved in this deranged crosstalk between free hUCMS and pSS T cells are required. In particular, we observed massive up-regulation of IDO1 at the mRNA and protein levels in IFN-g-stimulated hUCMS. IDO1, a master regulator of tolerance [17] , is normally expressed at low basal levels. One of the most powerful triggers of IDO1 expression is IFN-g, but this by itself could not account for the stable long-term tolerance occurring, for instance, during pregnancy. In fact, an IFN-g-dominated environment leads to rapid and intense tryptophan degradation, but it has been subsequently demonstrated that TGF-b is required to switch IDO activity into a selfmaintaining form of intracellular signalling activity, eventually leading to a stable regulatory environment. The IFNIDO axis is crucial to minimizing immune-mediated tissue injury secondary to infections and chronic inflammation by depleting the essential amino acid tryptophan. Indeed, products of tryptophan metabolism such as kynurenines display immunoregulatory activity and, besides inhibiting T cell proliferation, mediate differentiation into Treg cells by interacting with aryl hydrocarbon receptor expressed on the naive T cell surface. As reported, it is conceivable that IFN-g treatment leads to massive upregulation of iNOS at the mRNA but not the protein level, as occurs in murine hUCMS and other cell types [15] . This provides a clue about different pathways used by hUCMS to exert their immunomodulatory properties as compared with their murine counterpart. Indeed, in the latter, NO appears to play a crucial role in mediating immunoregulation.
The effects of hUCMS on the Th17 arm of the immune system deserve some consideration. A recent work reported that IDO blockade induced conversion of Tregs into Th17-like cells in rodent tumourdraining lymph nodes, while IL-6 seems to be crucial in such a scenario [14] . We know that IFN-g-pretreated hUCMS up-regulate IL-6 expression, hence we cannot assess whether the cytokine we detect in culture supernatant comes from hUCMS or dendritic cells [18] . However, in our system, where IDO is strongly expressed by CpS-hUCMS, conversion of Th17 into Treg cells may occur, in spite of the presence of hUCMS-derived IL-6. The longstanding paradigm that IL-6 has only proinflammatory functions was recently challenged by the demonstration that it may also display different properties in organ-specific autoimmune diseases such as T1D [19] . Therefore we speculate that it is not a matter of the cytokine itself, but rather of the cellular source, in this case hUCMS. Also, IL-6 was not associated with the direct immunosuppressive effect of hUCMS on CD4 + cells [18] .
Although we observed reduced percentages of Th17 cells in both pSS patients and HDs, a parallel decrease in IL-17 concentration was observed only in HD cocultures. These paradoxical findings could be explained by the fact that other IL-17-producing cells, insensitive to hUCMS, may be present within PBMCs. Double negative (DN) T cells are increased in autoimmune disorders such as SLE and pSS [20] and they infiltrate target organs, e.g. kidneys and minor salivary glands. These cells, isolated from pSS patients, are resistant to dexamethasone in vitro, while HD DN cells promptly reduced IL-17 expression in the presence of dexamethasone [13] . Here we have shown that DN Th17 cells are insensitive to the suppressive activity of CpS-hUCMS and maintain their resistance to dexamethasone. DN T cells are still being debated in immunology since conclusive data about their origin, function and fate are still missing. Therefore the overall beneficial effects of CpS-hUCMS against a lack of efficacy towards DN T cells in pSS requires further investigation in vivo in animal models of pSS.
In conclusion, we provided preliminary evidence that CpS-hUCMS represent a functional biohybrid artificial system where cellular molecular products are able to exert powerful immunomodulatory effects in vitro on T cells in pSS. Although our study focused on the evaluation of T cells as major players in pSS immunopathogenesis, additional in vitro studies assessing the effects of hUCMS on B cell subsets, and possibly on glandular epithelial cells, may be of interest. Although differences between in vitro settings and in vivo application are expected, we believe that in vivo therapeutic modalities using CpS-hUCMS may be built in preclinical animal models of autoimmune diseases. This may aid our understanding of whether the system devised in our laboratory represents a viable therapeutic alternative for pSS and other similar disorders.
Rheumatology key messages
. CpS-hUCMS but not free hUCMS have the capacity to reduce primary SS peripheral blood mononuclear cell proliferation. . CpS-hUCMS represent a functional biohybrid artificial system able to exert powerful in vitro immunomodulatory effects in primary SS. . CpS-hUCMS modulate FoxP3 and RORgt expression leading to the conversion of Th17 into Treg cells in primary SS.
